Next Science Ltd ( (AU:NXS) ) has shared an announcement.
Next Science Limited held its 2025 Annual General Meeting, where the Chair and CEO highlighted significant operational improvements and strategic advancements made in 2024. The company reduced its cash burn by US$7 million, improved margins, and achieved cash flow positivity for two non-consecutive months. With a US$5 million loan facility secured, Next Science is well-positioned for future growth. Clinical research published in 2024 demonstrated the effectiveness of its products, BLASTX and XPERIENCE, in reducing infections and inflammation, contributing to lower healthcare costs. The company also continued its large-scale study on periprosthetic joint infections, enrolling 1,220 patients by the end of 2024. Despite a decline in the Durable Medical Equipment channel, Next Science achieved record revenue of US$22.8 million, driven by strong direct and partner sales.
More about Next Science Ltd
Next Science is a medical technology company based in Sydney, Australia, with a research and development center in Florida, USA. Founded in 2012, the company focuses on developing and commercializing its proprietary XBIO™ technology to combat biofilm-based infections in human health. The XBIO™ technology is a unique, non-toxic solution effective in eradicating both biofilm-based and free-floating bacteria, and Next Science owns the patent-protected intellectual property for this technology.
Average Trading Volume: 170,597
Technical Sentiment Signal: Sell
Current Market Cap: A$28.05M
See more data about NXS stock on TipRanks’ Stock Analysis page.